TCPI INC
10-Q, EX-27, 2000-08-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: TCPI INC, 10-Q, EX-10.5, 2000-08-14
Next: DIAMOND TECHNOLOGY PARTNERS INC, 10-Q, 2000-08-14



<TABLE> <S> <C>

<ARTICLE>                                              5
<LEGEND>
         (The Company's Quarterly Report on Form 10-Q for the Period Ending June
30, 2000)
</LEGEND>
<CIK>                                                    0000924921
<NAME>                                                   WALTER USINOWICZ

<S>                                                      <C>
<PERIOD-TYPE>                                            3-MOS
<FISCAL-YEAR-END>                                        DEC-31-2000
<PERIOD-START>                                           JAN-01-2000
<PERIOD-END>                                             JUN-30-2000
<CASH>                                                   1,731
<SECURITIES>                                              0
<RECEIVABLES>                                            913
<ALLOWANCES>                                             332
<INVENTORY>                                              2,461
<CURRENT-ASSETS>                                          6,427
<PP&E>                                                   3,797
<DEPRECIATION>                                           1,928
<TOTAL-ASSETS>                                           21,951
<CURRENT-LIABILITIES>                                    4,002
<BONDS>                                                  0
                                    0
                                              2,259
<COMMON>                                                 30
<OTHER-SE>                                               17,112
<TOTAL-LIABILITY-AND-EQUITY>                             21,951
<SALES>                                                  2,312
<TOTAL-REVENUES>                                         2,312
<CGS>                                                    1,323
<TOTAL-COSTS>                                            1,323
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                          (4,592)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                      (4,592)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                             (4,592)
<EPS-BASIC>                                              (0.18)
<EPS-DILUTED>                                            (0.18)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission